Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by (18)F-FDG PET/CT: A case report

RATIONALE: The case reported the rapid remission of disease recurrence achieved adding foscarnet, a DNA polymerase inhibitor that interacts with fibroblast growth factor 2, to low molecular weight heparin and sunitinib for the first time in a patient with an anaplastic thyroid cancer (ATC). PATIENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannetta, Elisa, Isidori, Andrea M., Durante, Cosimo, Di Gioia, Cira, Longo, Flavia, Tombolini, Vincenzo, Bulzonetti, Nadia, Graziadio, Chiara, Pofi, Riccardo, Gianfrilli, Daniele, Verrienti, Antonella, Carletti, Raffaella, Filetti, Sebastiano, Lenzi, Andrea, Baroli, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312981/
https://www.ncbi.nlm.nih.gov/pubmed/28178124
http://dx.doi.org/10.1097/MD.0000000000005621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312981/
https://www.ncbi.nlm.nih.gov/pubmed/28178124
http://dx.doi.org/10.1097/MD.0000000000005621

Ejemplares similares